• Trials and Research

  Lower SPMS Risk Linked to Certain Initial Treatments, Study Reports

  Posted by MS News Today Moderator on February 7, 2019 at 11:44 am

  

  Initial treatment of RRMS with Gilenya, Tysabri or Lemtrada is associated with a lower risk of conversion to SPMS compared with interferon beta or Copaxone. Click here to learn more.

  What are your thoughts on this research?

  replied 7 years, 1 month ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply